Clinician Reviews
Advanced Search
My Account | Register

Sponsored CE/CME

Clinical Use of Incretin-Based Therapy in Type 2 Diabetes Mellitus
This supplement was sponsored by the Illinois Academy of Family Physicians and the Primary Care Education Consortium. This supplement was supported by an educational grant from Novo Nordisk Pharmaceuticals.
Incretin-based therapies have become important treatment options for the management of patients with type 2 diabetes mellitus (T2DM). While glucagon-like pepeptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have important benefits compared to other glucose-lowering agents, there are important differences among and between GLP-1R agonists and DPP-4 inhibitors. GLP-1R agonists are more potent glucose-lowering agents than DPP-4 inhibitors, and are also associated with weight loss. DPP-4 inhibitors are oral agents and generally do not cause nausea, which may be present in patients treated with GLP-1R agonists. Discussing these benefits and limitations and working collaboratively with the patient are crucial to improving treatment adherence. Simple strategies can be employed to address potential barriers associated with the use of incretins.

This CME supplement discusses the integration of incretin-based therapy in the treatment of T2DM and investigates methods of improving patient adherence.

Download PDF
PAGEPrev | 1 | Next
Quick Poll
Which best describes your use of mobile technology in clinical practice?


Submit Answer
View Results
Most Popular